CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1.
CD147
lymph node metastasis
lymphangiogenesis
melanoma
therapeutic targets
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Sep 2021
28 Sep 2021
Historique:
received:
21
07
2021
revised:
21
09
2021
accepted:
23
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Malignant melanoma is one of the most aggressive skin cancers and is characterized by early lymph node metastasis and the capacity to develop resistance to therapies. Hence, understanding the regulation of lymphangiogenesis through mechanisms contributing to lymphatic vessel formation represents a treatment strategy for metastatic cancer. We have previously shown that CD147, a transmembrane glycoprotein overexpressed in melanoma, regulates the angiogenic process in endothelial cells. In this study, we show a correlation between high CD147 expression levels and the number of lymphatic vessels expressing LYVE-1, Podoplanin, and VEGFR-3 in human melanoma lymph nodes. CD147 upregulates in vitro lymphangiogenesis and its related mediators through the PROX-1 transcription factor. In vivo studies in a melanoma model confirmed that CD147 is involved in metastasis through a similar mechanism as in vitro. This study, demonstrating the paracrine role of CD147 in the lymphangiogenesis process, suggests that CD147 could be a promising target for the inhibition of melanoma-associated lymphangiogenesis.
Identifiants
pubmed: 34638342
pii: cancers13194859
doi: 10.3390/cancers13194859
pmc: PMC8508014
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cell. 1999 Sep 17;98(6):769-78
pubmed: 10499794
Nature. 2020 Sep;585(7823):113-118
pubmed: 32814895
Cancer Res. 2005 Apr 15;65(8):3193-9
pubmed: 15833850
Eur J Cancer. 2009 May;45(8):1407-14
pubmed: 19157860
Int J Cancer. 1991 Apr 22;48(1):85-91
pubmed: 2019461
J Cutan Pathol. 2012 Sep;39(9):826-34
pubmed: 22804631
PLoS One. 2019 Apr 9;14(4):e0213831
pubmed: 30964887
Cell. 2000 Oct 13;103(2):239-52
pubmed: 11057897
Int J Cancer. 2006 Oct 15;119(8):1800-10
pubmed: 16721788
JAMA Oncol. 2018 Nov 1;4(11):1569-1575
pubmed: 30098152
Clin Exp Metastasis. 1991 May-Jun;9(3):259-72
pubmed: 2060184
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1566-73
pubmed: 26310281
Am J Pathol. 2010 Aug;177(2):1004-16
pubmed: 20616339
Genes Cancer. 2011 Dec;2(12):1146-58
pubmed: 22866206
Nat Cell Biol. 2000 Dec;2(12):E231-6
pubmed: 11146675
PLoS One. 2012;7(7):e40365
pubmed: 22808143
Med Res Rev. 2018 Sep;38(6):1769-1798
pubmed: 29528507
Leuk Res. 2011 Jan;35(1):24-6
pubmed: 20727589
Am J Pathol. 2005 Jan;166(1):209-19
pubmed: 15632013
Cancer Res. 1985 Jan;45(1):345-50
pubmed: 3965144
Physiol Rev. 2002 Jul;82(3):673-700
pubmed: 12087132
BMC Pulm Med. 2017 Dec 28;17(1):214
pubmed: 29282042
J Mol Cell Biol. 2015 Apr;7(2):143-53
pubmed: 25503107
Oncotarget. 2015;6(12):9766-80
pubmed: 25825981
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18746-7
pubmed: 24222686
Int J Clin Exp Pathol. 2019 Dec 01;12(12):4280-4288
pubmed: 31933828
Oncogene. 2004 Jan 29;23(4):956-63
pubmed: 14749763
J Cutan Pathol. 2009 Jul;36(7):772-80
pubmed: 19032379
Mol Oncol. 2019 Jun;13(6):1433-1449
pubmed: 31069961
EMBO J. 2002 Sep 2;21(17):4593-9
pubmed: 12198161
J Cell Mol Med. 2019 Feb;23(2):954-966
pubmed: 30421493
Angiogenesis. 2014 Apr;17(2):407-18
pubmed: 24048742
FEBS J. 2015 Nov;282(21):4187-200
pubmed: 26277583
Verh Dtsch Ges Pathol. 1999;83:270-5
pubmed: 10714221
Cancer Cell. 2009 Mar 3;15(3):220-31
pubmed: 19249680
J Biol Chem. 2001 Jun 1;276(22):19420-30
pubmed: 11278811
Oncogene. 2007 May 10;26(21):2997-3005
pubmed: 17130836
Cancer Chemother Pharmacol. 2016 Oct;78(4):815-24
pubmed: 27566701
Cancers (Basel). 2019 Nov 16;11(11):
pubmed: 31744072
Sci Rep. 2016 Jul 18;6:29914
pubmed: 27426915
Cancer Metastasis Rev. 2012 Dec;31(3-4):793-805
pubmed: 22733308
Anticancer Res. 2018 Nov;38(11):6139-6145
pubmed: 30396930
Biochem Biophys Res Commun. 2016 Sep 16;478(2):733-8
pubmed: 27507214
PLoS One. 2012;7(6):e39558
pubmed: 22745786
Int J Cancer. 2001 Apr 15;92(2):176-80
pubmed: 11291042
Cancer Biol Med. 2020 Aug 15;17(3):753-767
pubmed: 32944404
Clin Cancer Res. 2007 Jan 1;13(1):76-80
pubmed: 17200341
Methods Mol Biol. 2013;1066:103-11
pubmed: 23955737
Cells. 2020 Mar 20;9(3):
pubmed: 32244922
Oncol Lett. 2017 Oct;14(4):4670-4676
pubmed: 29085466
Clin Cancer Res. 2012 Dec 1;18(23):6416-25
pubmed: 23045246
Exp Dermatol. 2016 Aug;25(8):618-22
pubmed: 27060463
Sci Rep. 2019 Mar 18;9(1):4739
pubmed: 30894622
J Biol Chem. 2006 Dec 8;281(49):37576-85
pubmed: 17050542
Acta Clin Belg. 2020 Dec;75(6):379-387
pubmed: 31210586
Int J Dev Biol. 2011;55(4-5):483-94
pubmed: 21858772
Am J Pathol. 1999 Feb;154(2):385-94
pubmed: 10027397
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):148-160
pubmed: 26705849
Blood. 2009 Dec 24;114(27):5547-56
pubmed: 19837976
Cancer Res. 1995 Jan 15;55(2):434-9
pubmed: 7812975
Am J Pathol. 2003 Jun;162(6):1951-60
pubmed: 12759251
PLoS One. 2016 Jul 06;11(7):e0158839
pubmed: 27383632
FASEB J. 2002 Jul;16(9):922-34
pubmed: 12087053
J Gastroenterol Hepatol. 2016 Feb;31(2):459-66
pubmed: 26312403
Front Oncol. 2020 Nov 27;10:576190
pubmed: 33330052
Blood. 2007 Feb 1;109(3):1010-7
pubmed: 17032920
J Cutan Pathol. 2015 Oct;42(10):699-711
pubmed: 26264662
J Invest Dermatol. 2004 May;122(5):1293-301
pubmed: 15140234